EP
PGNX

Elkfork Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Elkfork Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-24,174
Closed -$152K – 1075
2018
Q3 		$152K Buy
24,174
+1,734
+8% +$13.3K ﹤0.01% 897
2018
Q2 		$180K Hold
22,440
– – ﹤0.01% 823
2018
Q1 		$167K Buy
22,440
+5,270
+31% +$35K ﹤0.01% 837
2017
Q4 		$102K Buy
17,170
+4,352
+34% +$26.4K ﹤0.01% 931
2017
Q3 		$94K Buy
12,818
+3,094
+32% +$19.7K ﹤0.01% 915
2017
Q2 		$66K Buy
9,724
+5,202
+115% +$38.4K ﹤0.01% 943
2017
Q1 		$43K Buy
+4,522
New +$45.1K ﹤0.01% 933

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Elkfork Partners's PGNX Position: Q4 2018 in Review

Elkfork Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 24,174 shares — an estimated $152K sold.

Elkfork Partners first reported a position in PGNX in Q1 2017 and held it in 7 quarters. The position peaked at $180K in Q2 2018. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

  • Elkfork Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Elkfork Partners sold 24,174 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $152K.
  • Elkfork Partners first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 7 quarters.
  • Elkfork Partners's Progenics Pharmaceuticals Inc position peaked at $180K in Q2 2018.
  • 150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Elkfork Partners's 13F filing for Q4 2018, filed 13 Feb 2019.